LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$57.9 by the time of writing, with a trading volume of HK$20.2056 million. On November 4, the company announced that five research abstracts had been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH). The company shared further details about its investigational drugs, LBL-034 and LBL-076, with multiple research abstracts accepted by the ASH conference. Notably, one clinical study on LBL-034 was chosen as the first oral presentation on the opening day, showcasing the latest efficacy and safety data for LBL-034 in patients with relapsed/refractory multiple myeloma.